Table 1 Baseline characteristics of patients with NMOSD and MS.

Age, median [IQR]

50.0 [45.5–60.5]

44.0 [35.0–53.8]

< 0.001

Age at onset, median [IQR]

43.0 [33.5–52.0]

32.0 [23.0–39.8]

< 0.001

Female, n (%)

37 (90.2)

65 (70.7)

0.014

Education, median [IQR]

12.0 [12.0–16.0]

16.0 [12.0–16.0]

0.049

Disease duration, years, median [IQR]

9.0 [4.5–13.0]

11.0 [7.3–14.0]

0.030

Last Clinical Attack location, n (%)

0.076

ON

8 (19.5)

16 (17.4)

TM

26 (63.4)

36 (39.1)

Brain

5 (12.2)

31 (33.7)

ON + TM

0

2 (2.2)

ON + Brain

1 (2.4)

2 (2.2)

TM + Brain

1 (2.4)

5 (5.4)

EDSS, median [IQR]

2.5 [2.0–4.0]

2.0 [1.0–3.5]

0.041

0.912

PST score, median [IQR]

41.0 [19.0–53.5]

47.0 [36.3–63.0]

0.019

0.723

Immune modulatory agent^a, n (%)

40 (97.6)

85 (92.4)

0.247

B-cell depleting treatment (BCDT)

12 (29.3)

Non-B-cell depleting treatment

28 (68.3)

High-efficacy treatment

Low-efficacy treatment

Blood biomarker

sGFAP, pg/mL, median [IQR]

127.2 [102.6–229.3]

90.0 [68.1–129.0]

< 0.001

0.036

sNfL, pg/mL, median [IQR]

12.9 [9.1–20.3]

9.8 [7.6–14.7]

0.033

0.929